Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Allogeneic stem cell transplantation for multiple myeloma

W I Bensinger1, D Buckner, G Gahrton

  • 1Fred Hutchinson cancer Research Center, University of Washington, Seattle, USA.

Hematology/Oncology Clinics of North America
|February 1, 1997
PubMed
Summary

High-dose chemotherapy with allogeneic marrow transplantation can cure advanced multiple myeloma. However, high transplant-related mortality necessitates developing safer preparative regimens and better ways to prevent complications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Randomized Comparison of Doxorubicin and Doxorubicin-DNA in the Treatment of Acute NonLymphoblastic Leukemia.

Leukemia & lymphoma·2016
Same author

Cytogenetic Findings and Survival in B-cell Chronic Lymphocytic Leukemia. Second IWCCLL Compilation of Data on 662 Patients.

Leukemia & lymphoma·2016
Same author

Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma.

Bone marrow transplantation·2016
Same author

A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma.

Blood cancer journal·2016
Same author

Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party.

Leukemia·2016
Same author

Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group.

Leukemia·2015

Area of Science:

  • Hematology
  • Oncology
  • Transplantation Immunology

Background:

  • Advanced multiple myeloma is a hematologic malignancy with limited curative options.
  • High-dose chemotherapy followed by allogeneic stem cell transplantation offers a potential cure for select patients.
  • Current treatment protocols face challenges with significant transplant-related mortality.

Purpose of the Study:

  • To evaluate the efficacy of high-dose chemotherapy and allogeneic marrow transplantation for advanced multiple myeloma.
  • To identify the limitations and challenges associated with this intensive treatment approach.
  • To outline future research directions for improving outcomes in multiple myeloma transplantation.

Main Methods:

  • Administration of high-dose chemotherapy, potentially combined with total body irradiation.

Related Experiment Videos

  • Performance of allogeneic marrow transplantation.
  • Monitoring of patient outcomes, including efficacy and transplant-related mortality.

    • Main Results:

    • Allogeneic marrow transplantation can be curative for some patients with advanced multiple myeloma.
    • A significant limitation is the high transplant-related mortality associated with the procedure.
    • Graft-versus-host disease and infections are key complications.

    Conclusions:

    • Allogeneic marrow transplantation is a viable, albeit high-risk, curative strategy for advanced multiple myeloma.
    • Future research must focus on reducing preparative regimen toxicity.
    • Improving prophylaxis against infection and graft-versus-host disease is crucial.
    • Enhancing the graft-versus-leukemia effect is a critical goal for improving long-term survival.